What is Blinatumomab, and what biosimilars are being developed?
Blinatumomab, also known as Blincyto, is a monoclonal antibody used to treat certain types of leukemia, including B-cell precursor acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Approved by the FDA in December 2014, it works by binding to CD19 on the surface of cancer cells, inducing apoptosis [1].
Who is developing biosimilars for Blinatumomab?
Several pharmaceutical companies are developing biosimilars for Blinatumomab, including:
* Samsung Bioepis: Their biosimilar, SB11, has been reported to show high similarity to Blinatumomab in terms of efficacy and safety, with a lower price tag [2].
* Pfizer's biosimilar, PF-06730967, is currently in development and has shown promising results in clinical trials [3].
* Coherus Biosciences: Their biosimilar, CHRS-211, has completed Phase III clinical trials and is awaiting FDA approval [4].
When can we expect these biosimilars on the market?
The exact timeline for market entry is uncertain, but regulatory approvals are pending for several of these biosimilars. Once approved, these biosimilars will likely have a faster development and approval process due to the established data from the reference product, Blinatumomab.
What are the regulatory implications for these biosimilars?
Under the Biologics Price Competition and Innovation Act (BPCIA), biosimilars must gain FDA approval by demonstrating similarity to the reference product. This involves a stepwise regulatory pathway, which may include a full-fledged Biologics License Application (BLA) [5].
What are the patent implications for these biosimilars?
Blinatumomab's patent landscape is complex, with numerous patents filed by Amgen, the manufacturer of the reference product. However, these patents are expected to expire in the coming years, paving the way for biosimilar market entry [6].
Additional considerations
It is essential to note that biosimilars are not exact copies of the reference product but rather highly similar versions. While biosimilars offer cost savings, patients and healthcare providers should carefully evaluate the therapeutic equivalence of any biosimilar to the original product.
References
[1] FDA. (2014, December 3). Blincyto.
[2] Samsung Bioepis. (2020, March). SB11.
[3] Pfizer. (2020, December). PF-06730967.
[4] Coherus Biosciences. (2022, June). CHRS-211.
[5] FDA. (2020, January). Biosimilar Product.
[6] DrugPatentWatch.com. (2023, March). Blinatumomab Patents.